Clin2
NCT07123207Possibly a fitRecruiting

Probiotic with infliximab for Crohn's disease

Mild to Severe Crohns Disease

Part of Digestive system, Immune system & allergy clinical trials.

This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
24 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have been diagnosed with Crohn's disease.
  • You are currently taking infliximab (Remicade) for your Crohn's.
  • Your Crohn's is active (symptoms like diarrhea, belly pain, or weight loss).
  • You do not have a serious infection, liver/kidney problems, or diabetes that isn't well-controlled.
  • You are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07415473Not yet recruiting· Phase 4
Gut bacteria with infliximab for Crohn's disease healing

This study tests whether adding a specific gut bacteria (Akkermansia muciniphila) to the standard Crohn's treatment infliximab helps heal the intestinal lining better. This could improve long-term control of Crohn's disease.

NCT06758024Recruiting
Optimizing infliximab for inflammatory bowel disease

This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.

Santiago
NCT07047339Recruiting· Phase 2/Phase 3
Probiotic 6600 for colitis patients

This trial tests whether adding Probiotic 6600 to your usual treatment can help manage colitis, including ulcerative colitis or Crohn's disease. It aims to see if the probiotic improves symptoms and is safe to use.

Shanghai
NCT06059989Recruiting· Phase 3
Testing a new form of infliximab for Crohn's disease

This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.

Amsterdam, North Holland
NCT07417696Not yet recruiting· Phase 4
Adding palmitoleic acid to infliximab for Crohn's disease

This study tests whether adding a natural fatty acid (palmitoleic acid) to a standard Crohn's treatment (infliximab) is better at healing the lining of the intestine. It aims to see if this combination can calm the disease and reduce symptoms.

NCT07120152Not yet recruiting
Studying the body's response to infliximab injection for inflammatory bowel disease

This study tests a medicine called infliximab, given as an injection under the skin, to see how the body processes it in people with inflammatory bowel disease (Crohn's disease or ulcerative colitis). It may help find the best dose for your condition.

Hear when a new Mild to Severe Crohns Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.